Arca biopharma, Nuvelo deal

Nuvelo and cardiovascular company Arca agreed to reverse merge. Arca shareholders will own 67% of the combined company, and Nuvelo shareholders will own 33%. The combined company will retain Arca's name and headquarters and will apply for a new NASDAQ ticker. Richard Brewer, president and CEO of Arca, will become CEO of the combined company. Arca's Michael Bristow will retain his position as chairman and chief science and medical officer. ...